Format

Send to

Choose Destination
Respir Med. 2008 Dec;102(12):1833-8. doi: 10.1016/j.rmed.2008.07.007. Epub 2008 Aug 22.

Non-reversible airway obstruction in never smokers: results from the Austrian BOLD study.

Author information

1
Department of Pulmonary Medicine, Paracelsus Medical University Hospital, Salzburg, Austria. b.lamprecht@salk.at

Abstract

BACKGROUND:

The presence of non-reversible airway obstruction (AO) in never smokers has only received limited attention until now.

METHODS:

We analyzed data from the Austrian Burden of Obstructive Lung Disease (BOLD) study. We defined non-reversible AO as post-bronchodilator FEV(1)/FVC <0.7 which corresponds to COPD I and higher (COPD I+) according to current GOLD guidelines. Significant AO was defined as FEV(1)/FVC <0.7 and FEV(1) <80% predicted (GOLD II and higher, GOLD II+). The prevalence and characteristics of non-reversible AO in never smokers were analyzed in relation to the severity of the disease.

RESULTS:

Never smokers comprised 47.3% of the study population. Non-reversible AO was seen in 18.2% of never smokers, and 5.5% of never smokers fulfilled criteria for significant non-reversible AO (GOLD stage II+). Therefore, the resulting population prevalence of significant non-reversible AO (GOLD stage II+) was 2.6%. Never smokers with non-reversible AO were predominantly female and slightly older. The airway obstruction was found to be less severe as compared with ever smokers. Despite this, 20% of never smokers with significant non-reversible AO (GOLD stage II+) reported respiratory symptoms and 50% reported impairment of quality of life. This burden of illness in never smokers was similar to that in smokers when severity of AO was taken into account.

CONCLUSION:

Approximately every third subject with non-reversible AO has never smoked, yet still demonstrates a substantial burden of symptoms and impairment of quality of life. Never smokers should receive far greater attention when efforts are undertaken to prevent and treat chronic airway obstruction.

PMID:
18722100
DOI:
10.1016/j.rmed.2008.07.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center